Molecule
Oxymetazoline is a vasoconstrictor indicated for the topical treatment of persistent facial erythema associated with rosacea in adults. It is available as cream and eye drops for topical and ophthalmic use. MedsAcross supplies Oxymetazoline for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Oxymetazoline Hydrochloride Cream, 1% is indicated for the topical treatment of persistent facial erythema associated with rosacea in adults. Oxymetazoline Hydrochloride Cream is an alpha 1A adrenoceptor agonist indicated for the topical treatment of persistent facial erythema associated with rosacea in adults.
Source: US FDA prescribing information
Oxymetazoline is an alpha 1A adrenoceptor agonist. Oxymetazoline acts as a vasoconstrictor.
Source: US FDA prescribing information
For topical use only. Oxymetazoline Hydrochloride Cream is not for oral, ophthalmic, or intravaginal use. Apply a pea-sized amount of Oxymetazoline Hydrochloride Cream, once daily in a thin layer to cover the entire face (forehead, nose, each cheek, and chin) avoiding the eyes and lips. Wash hands immediately after applying Oxymetazoline Hydrochloride Cream. Not for oral, ophthalmic, or intravaginal use. Prime pump bottle before initial use and discard product from first three pumps. Apply a pea-sized amount once daily in a thin layer to cover the entire face (forehead, nose, each cheek, and chin) avoiding the eyes and lips. Wash hands after application.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Alpha-adrenergic agonists as a class may impact blood pressure. Advise patients with cardiovascular disease, orthostatic hypotension, and/or uncontrolled hypertension or hypotension to seek medical care if their condition worsens. Use with caution in patients with cerebral or coronary insufficiency, Raynaud's phenomenon, thromboangiitis obliterans, scleroderma, or Sjögren's syndrome and advise patients to seek medical care if signs and symptoms of potentiation of vascular insufficiency develop. Advise patients to seek immediate medical care if signs and symptoms of acute narrow-angle glaucoma develop.
Source: US FDA prescribing information
Most common adverse reactions (incidence ≥ 1%) are application site dermatitis, worsening inflammatory lesions of rosacea, application site pruritis, application site erythema, and application site pain.
Source: US FDA prescribing information
Anti-hypertensives/Cardiac Glycosides Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as beta-blockers, anti-hypertensives and/or cardiac glycosides is advised. Caution should also be exercised in patients receiving alpha 1 adrenergic receptor antagonists such as in the treatment of cardiovascular disease, benign prostatic hypertrophy, or Raynaud's disease.
Source: US FDA prescribing information
Store at 20°C-25°C (68°F-77°F), excursions permitted to 15°C-30ºC (59°F- 86ºF).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
3 presentations of Oxymetazoline, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Rhofade 1% creamTopical | Mayne Pharma | US FDA | Available on request |
| Oxymetazoline 1% creamTopicalGeneric name | — | US FDA | Available on request |
| Upneeq 1 mg/mL eye dropsOphthalmic | RVL Pharmaceuticals | US FDA | Available on request |
2 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 30 May 1986 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Oxymetazoline in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 3 presentations of Oxymetazoline and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 2 brand names for Oxymetazoline, including Rhofade, Upneeq.
Yes. The US FDA first approved Oxymetazoline on 30 May 1986, according to Drugs@FDA.
No listed presentation of Oxymetazoline is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Oxymetazoline is classified under ATC code D11AX27 (Oxymetazoline).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.